Bimekizumab 4-year Efficacy in High-impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from BE BRIGHT
Main Article Content
Keywords
psoriasis, bimekizumab, long-term efficacy, high-impact areas, scalp, nail, palmoplantar, quality of life, clinical trial
Abstract
References
1. Merola JF et al. Dermatol Ther 2018;31:e12589
2. Cashman MW et al. Clin Dermatol 2010;28:420–5
3. Adams R et al. Front Immunol 2020;11:1894
4. Warren RB et al. N Engl J Med 2021;385:130–41, NCT03412747
5. Reich K et al. Lancet 2021;397:487–98, NCT03370133
6. Reich K et al. N Engl J Med 2021;385:142–52, NCT03536884
7. Gordon KB et al. Lancet 2021;397:475–86, NCT03410992
8. Merola JF et al. Presented at EADV 2023; P2547
9. Strober B et al. Br J Dermatol 2023;188:749–59, NCT03598790
10. European Medicines Agency. Bimekizumab Summary of Product Characteristics. 2023. Available at: https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-productinformation_en.pdf [Accessed September 2024].
2. Cashman MW et al. Clin Dermatol 2010;28:420–5
3. Adams R et al. Front Immunol 2020;11:1894
4. Warren RB et al. N Engl J Med 2021;385:130–41, NCT03412747
5. Reich K et al. Lancet 2021;397:487–98, NCT03370133
6. Reich K et al. N Engl J Med 2021;385:142–52, NCT03536884
7. Gordon KB et al. Lancet 2021;397:475–86, NCT03410992
8. Merola JF et al. Presented at EADV 2023; P2547
9. Strober B et al. Br J Dermatol 2023;188:749–59, NCT03598790
10. European Medicines Agency. Bimekizumab Summary of Product Characteristics. 2023. Available at: https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-productinformation_en.pdf [Accessed September 2024].